Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance
Journal of Medicinal Chemistry · 27.06.2024 · 67 (12) · 10190-10210
DOI: 10.1021/acs.jmedchem.4c00366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.06.2024. Verfasst von Ziru Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Institute of Molecular Plus, Frontiers Science Center for Synthetic Biology (Ministry of Education o…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Resistance, Neoplasm, Oxaliplatin, Quantitative Structure-Activity Relationship. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Tianjin University, National Natural Science Foundation of China, Gudui BioPharma Technology Inc..
Abstract (Originalsprache)
Oxaliplatin-based chemotherapy has proven to be one of the most effective treatments for advanced or metastatic colorectal cancer. However, increasing clinical resistance to oxaliplatin poses unprecedented challenges for both patients and clinicians. Despite extensive efforts to combat this issue, to date, no new molecules have been discovered that can successfully replace oxaliplatin. With the aim of developing a new generation of Pt(II)-based anticancer agents in response to the challenges of oxaliplatin-induced drug resistance, we performed a systematic screening of new Pt(II)-complexes with a quantitative structure-activity relationship (QSAR) study based on their antiresistance activity against oxaliplatin-resistant colon cancer cells. The results revealed that both the structure and chirality of the chelating ligand had a significant impact on the antiresistance properties of the Pt(II)-complexes. Our study culminated in the identification of chiral R-binaphthyldiamine-ligated Pt(II)-malonatoglycoconjugates that can completely counteract oxaliplatin resistance with excellent in vitro and in vivo potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Institute of Molecular Plus, Frontiers Science Center for Synthetic Biology (Ministry of Education of China), Tianjin Key Laboratory for Modern Drug Delivery & High-Effic…
- Department of Biology, Tianjin Key Laboratory of Innovative Drugs Targeting the Central Nervous System, Gudui BioPharma Technology Inc., 5 Lanyuan Road, Huayuan Industrial Park, Tianjin 300384, P. R. China.
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, West Huanhu Road, Hexi District, Tianjin 300060, P. R. China.
- Transplantation Center, Tianjin First Central Hospital, 24 Fukang Road, Nankai District, Tianjin 300192, P. R. China.
ORCID-Profile: Jun Xu, Qingzhi Gao
Förderung
- Tianjin University
- National Natural Science Foundation of China
- Gudui BioPharma Technology Inc.
Zitieren
APA
Sun, Z., Han, J., Xu, J., Song, W., Cui, Y., Liu, Y., Yang, L., Meng, X., Huang, J., Gao, Q., & Liu, S. (2024). Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance. Journal of Medicinal Chemistry, 67(12), 10190-10210. https://doi.org/10.1021/acs.jmedchem.4c00366
Vancouver
Sun Z, Han J, Xu J, Song W, Cui Y, Liu Y, et al. Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance. Journal of Medicinal Chemistry. 2024;67(12):10190-10210. doi:10.1021/acs.jmedchem.4c00366
BibTeX
@article{Sun2024,
author = {Sun, Ziru and Han, Jianbin and Xu, Jun and Song, Weijie and Cui, Yujun and Liu, Yang and Yang, Liu and Meng, Xiaoqi and Huang, Jie and Gao, Qingzhi and Liu, Shengnan},
title = {Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {12},
pages = {10190--10210},
doi = {10.1021/acs.jmedchem.4c00366}
}
EUVIMED